Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research note on Friday, November 15th.

Aethlon Medical Trading Up 5.8 %

AEMD opened at $0.37 on Wednesday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.35. The business’s fifty day simple moving average is $0.39 and its 200-day simple moving average is $0.42. The company has a market capitalization of $5.11 million, a price-to-earnings ratio of -0.13 and a beta of 1.79.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.